Following publication of the original article \[[@CR1]\], the authors reported that they had supplied the incorrect figure for publication.

**Cao et al. BMC Cancer (2018) 18:1293.**

**https://doi.org/10.1186/s12885-018-5205-9**

Following publication of the original article \[[@CR1]\], the authors reported that they had supplied the incorrect figure for publication. The correct figure is displayed below. The authors apologise for the error.

Fig. 2miR-18a promotes cell proliferation in EBV-positive lymphoma cells. **a** miR-18a promoted tumor cell growth in vitro in EBV-positive lymphoma cell lines. CCK-8 cell viability assay was performed after the transfection of miR-18a mimics or miR-18a inhibitor into EBV-positive lymphoma cell lines (P3HR-1, Raji, EBV infected BJAB) and the EBV-negative lymphoma cell line BJAB. The data represented the mean values of five repeats. The data are shown as the means±SD (Student T-test, \**p* \< 0.05). **b** Flow cytometry analysis of the cell cycle after the transfection of miR-18a. **c** Cell cycle distribution of cells in S phase. The data were presented as the means±SD of four replicates (Student T-test, \**p* \< 0.05; \*\**p* \< 0.01)
